Latest Lead News

Shine Justice Ltd reported a revenue increase to $204.4 million in FY25 despite a dip in adjusted net profit after tax, driven by strategic restructuring and a sharpened focus on personal injury and international mass torts. The company is investing in technology and expanding its US footprint to fuel growth in FY26.

dorsaVi appoints Mathew Regan as Group CEO to spearhead commercialisation of next-gen RRAM-enabled AI and robotics technologies, aiming for global expansion.

Ramsay Health Care has announced a fully franked ordinary dividend of AUD 0.40 per share for the six months ending June 2025, signaling steady returns for shareholders.

Raiz Invest Limited reported a robust FY25 with 15% revenue growth and a 147% jump in underlying EBITDA, driven by innovative products and AI-powered marketing. The company projects further earnings growth in FY26 amid expanding customer base and strategic partnerships.

RPM Automotive Group reported a mixed FY25 with a slight revenue decline but improved profitability and launched a tyre recycling initiative signaling a strategic shift.

Raiz Invest reported robust FY25 results with 15% revenue growth and a near break-even net loss, underpinned by strong customer and funds growth. The fintech’s strategic innovations and partnerships set a positive tone for FY26.

Control Bionics Limited has announced a $2.06 million non-renounceable rights issue to fund the commercial expansion of its NeuroStrip device and bolster NeuroNode operations. The capital raise is underwritten to approximately $1.15 million by major shareholders and strategic partners.

Zoono Group Limited reported a 19.1% revenue increase to NZ$1.25 million for FY2025, alongside a significantly reduced net loss. The company is pivoting towards B2B markets, focusing on antimicrobial and shelf-life extension technologies, supported by a recent AUD 1.78 million capital raise.

Lynas Rare Earths has launched a fully underwritten A$750 million equity raising to fund its ambitious Towards 2030 growth strategy, aiming to expand rare earths production and downstream capabilities outside China.

Lynas Rare Earths reported FY25 results featuring record NdPr output and the first commercial heavy rare earths production outside China, alongside a $750 million equity raise to fund its ambitious Towards 2030 growth strategy.

Dimerix Limited reported a 22% reduction in its FY2025 loss to $13.25 million, driven by strong licensing revenues and advancing its pivotal Phase 3 clinical trial for DMX-200. The company secured new global partnerships valued at up to AU$1.4 billion, bolstering its cash reserves and commercial prospects.

Emyria Limited reports a reduced net loss of $3.14 million for FY2025, driven by strategic expansion in psychedelic-assisted mental health treatments and key partnerships including insurer Medibank. The company advances clinical services while continuing R&D on proprietary medicines.